EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Ablynx NV's enterprise value is €0.97 Mil.
Ablynx NV's EBITDA for the trailing twelve months (TTM) ended in Dec. 2017 was €-98.07 Mil. Therefore, Ablynx NV's EV-to-EBITDA for today is -0.01.
The historical rank and industry rank for Ablynx NV's EV-to-EBITDA or its related term are showing as below:
XBRU:ABLXS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -46.1 Med: -10.05 Max: 135.5
Current: -33.62
During the past 12 years, the highest EV-to-EBITDA of Ablynx NV was 135.50. The lowest was -46.10. And the median was -10.05.
XBRU:ABLXS's EV-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 9.67
vs XBRU:ABLXS: -33.62
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-25), Ablynx NV's stock price is €0.00.
Ablynx NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2017 was €0.000. Therefore, Ablynx NV's PE Ratio for today is N/A.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Ablynx NV EV-to-EBITDA Historical Data
The historical data trend for Ablynx NV's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Ablynx NV's EV-to-EBITDA
For the Biotechnology subindustry, Ablynx NV's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ablynx NV's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ablynx NV's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Ablynx NV's EV-to-EBITDA falls into.
Ablynx NV EV-to-EBITDA Calculation
Ablynx NV's EV-to-EBITDA for today is calculated as:
Ablynx NV's current Enterprise Value is €0.97 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ablynx NV's EBITDA for the trailing twelve months (TTM) ended in Dec. 2017 was €-98.07 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ablynx NV (XBRU:ABLXS) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Ablynx NV's share price for today is €0.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ablynx NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2017 was €0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Ablynx NV's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Ablynx NV is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. It has 45 proprietary and partnered programs in development in various therapeutic areas including inflammation, hematology, immuno-oncology, oncology and respiratory disease. It has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The company generates revenue from research collaboration agreements and from government grants.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XBRU:ABLXS has been successfully added to your 